A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Omeros Corporation (“Omeros,” the “Company” or “we”) is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic diseases, including complement-mediated diseases and cancers related to dysfunction of the immune system, as well as addictive and compulsive disorders. Complement-targeted Therapeutic Development Programs We are advancing multiple development programs focused on diseases and disorders associated with the complement system, a group of specialized proteins that protect against invasive pathogens as well as damaged cells inside the body and comprise an important part of the body’s immune system. When triggered, the various components of complement cooperate to generate an immune response that fights infection and clears damaged or dead cells, maintaining healthy function of the body’s systems.
| Metric | TTM | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 74M | 112M | - | 65M | 42M |
| Net Income | -121M | -138M | -84M | -127M | -53M | -67M |
| EPS | $-2.02 | $-2.41 | $-1.71 | $-2.61 | $-1.17 | $-1.65 |
| Free Cash Flow | -105M | -100M | -60M | -104M | -37M | -52M |
| ROIC | -55.0% | -68.5% | -84.2% | -92.4% | -65.8% | -63.7% |
| Gross Margin | - | 98.8% | 99.2% | - | 98.3% | 96.6% |
| Debt/Equity | 0.00 | -1.97 | -0.03 | -0.02 | -30.07 | -2.13 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -129M | -157M | -146M | -112M | -44M | -54M |
| Operating Margin | 0.0% | -212.6% | -130.6% | - | -67.7% | -130.4% |
| ROE | 0.0% | - | - | - | - | - |
| Shares Outstanding | 71M | 57M | 49M | 49M | 46M | 40M |
OMEROS CORP passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 98.2%. At current prices, the estimated annualized return to fair value is -31.9%.
OMEROS CORP (OMER) has a 5-year average return on invested capital (ROIC) of -74.9%. This is below average and may indicate limited pricing power.
OMEROS CORP (OMER) has a market capitalization of $839M. It is classified as a small-cap stock.
OMEROS CORP (OMER) does not currently pay a regular dividend.
OMEROS CORP (OMER) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
OMEROS CORP (OMER) reported annual revenue of $74 million in its most recent fiscal year, based on SEC EDGAR filings.
OMEROS CORP (OMER) has a net profit margin of -187.0%. The company is currently unprofitable.
OMEROS CORP (OMER) generated $-100 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
OMEROS CORP (OMER) reported earnings per share (EPS) of $-2.41 in its most recent fiscal year.
OMEROS CORP (OMER) has a 5-year average gross margin of 98.2%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 12 years of financial data for OMEROS CORP (OMER), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
OMEROS CORP (OMER) has a book value per share of $-2.11, based on its most recent annual SEC filing.
No recent press releases.